IO Biotech Elects New Director at Annual Meeting

The latest update is out from IO Biotech ( (IOBT) ).

On June 5, 2025, IO Biotech, Inc. held its 2025 Annual Meeting of Stockholders where two key proposals were addressed. David Smith was elected as a Class I director, and the appointment of EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.

The most recent analyst rating on (IOBT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on IO Biotech stock, see the IOBT Stock Forecast page.

Spark’s Take on IOBT Stock

According to Spark, TipRanks’ AI Analyst, IOBT is a Neutral.

IO Biotech faces significant challenges due to its financial instability and lack of revenue. However, the progress in clinical trials and secured financing improve its future prospects, though it remains speculative. The technical analysis suggests neutral momentum, and the valuation highlights typical risks associated with biotech stocks awaiting commercialization.

To see Spark’s full report on IOBT stock, click here.

More about IO Biotech

Average Trading Volume: 177,031

Technical Sentiment Signal: Buy

Current Market Cap: $105.4M

See more data about IOBT stock on TipRanks’ Stock Analysis page.